IDEAYA Biosciences Q3 loss widens to $125.7M
IDEAYA Biosciences reported a Q3 2026 net loss of $125.7M, up from $112.5M in Q2, with collaboration revenue rising to $10.2M. Cash reserves fell to $1.15B. The company submitted darovasertib for FDA approval and plans Phase 3 trials, maintaining its cash runway guidance into 2030.
How this was made
The 30-second read
Why it matters
The Q3 earnings miss and cash decline are likely to trigger short‑term selling pressure, though upcoming trial data could provide a catalyst.
Market read
Earnings release provides fresh material for traders; the loss widening and cash burn are key drivers.
What to watch
Potential cost savings from OptimUM-010 closure and pipeline progress could mitigate cash concerns.
Background
IDEAYA Biosciences is a clinical‑stage biotech focused on oncology, listed on NASDAQ.
Ticker impact
IDEAYA Biosciences reported a Q3 loss of $125.7M, wider than the prior quarter, and disclosed new FDA filing and trial initiations.
likely pressure as the market prices in the larger loss and cash depletion
Earnings miss and increased cash outflow are fresh, material information that typically depresses biotech stocks.
Market effects
May weigh on other late‑stage biotech peers as investors reassess cash‑runway risks.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the upcoming trial data exceed expectations, the stock could rebound despite the loss.
Key entities
- companyIDEAYA Biosciences
NASDAQ‑listed biotech reporting Q3 results.
- partnerServier
Collaborator on the OptimUM-011 trial.
